BioCentury
ARTICLE | Clinical News

Lipid-modified peptides: Will begin a Phase I study

March 28, 1994 8:00 AM UTC

United Biomedical Inc., Hauppauge, N.Y. Product: Lipid-modified peptides capable of stimulating HIV-specific cytotoxic T lymphocyte responses Indication: Stand-alone AIDS treatment or as a prophylacti...